About: dbpedia:Vismodegib   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : platform.yourdatastories.eu:8890 associated with source document(s)

Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011.

AttributesValues
rdfs:comment
  • Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011.
foaf:depiction
  • External Image
ATC prefix
  • L01
ATC suffix
  • XX43
Bioavailability
CAS number
  • 879085-55-9
ChEBI
  • 66903
DrugBank
  • DB08828
FDA UNII code
  • 25X868M3DS
IUPAC name
  • 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
PubChem
  • 24776445
thumbnail
is product of
Faceted Search & Find service v1.13.91 as of Nov 14 2017


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3212 as of Mar 29 2016, on Linux (x86_64-unknown-linux-gnu), Single-Server Edition (68 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2026 OpenLink Software